The action of decorin in anti-fibrosis and anti-cancer.
- Author:
Weifeng MA
1
;
Yi TAN
;
Shaohui CAI
;
Hongyuan CHEN
;
Jun DU
;
Shaoxi CAI
Author Information
1. Key Laboratory for Biomechanics & Tissue Engineering of the State Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400044, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Antineoplastic Agents;
pharmacology;
Decorin;
Extracellular Matrix Proteins;
chemistry;
pharmacology;
Fibrosis;
prevention & control;
Humans;
Proteoglycans;
chemistry;
pharmacology;
Receptor, Epidermal Growth Factor;
antagonists & inhibitors;
Recombinant Proteins;
pharmacology;
Transforming Growth Factor beta1;
antagonists & inhibitors
- From:
Journal of Biomedical Engineering
2007;24(1):222-225
- CountryChina
- Language:Chinese
-
Abstract:
Decorin (DCN) is a member of the small leucine-rich proteoglycan gene family. Many studies indicated that DCN inhibited fibrosis and scar-formation by neutralization of TGF-P and interfering the binding of TGF-beta with its receptor, which induced ectopic deposition of extracellular matrix. Additionally, DCN can prevent the proliferation and metastasis of tumor cells by activating EGFR/MAPK/p21 signal pathway and inhibiting the cell proliferation pathway mediated by EGF-EGFR. It is suggested that the recombinant DCN had potential pharmaceutical potency in treatment of chronic fibrosis and neoplasm for its critical biological activities and low immunogenicity.
